Home Articles Page 103

Articles

Welcome to the ARCHIVE of Pharma Marketing News articles. All articles are FREE! No subscription is required to download these articles from past issues. Articles become available to non-subscribers approximately two months after publication. To obtain articles as soon as they are published, you must subscribe to the email newsletter service. Subscription is free and supported by advertising.

Pharma Marketing News – Special Supplements

Pharma Marketing News is the monthly e-newsletter of the Pharma Marketing Network (www.pharma-mkting.com). It is packed with facts, opinions, and case studies based upon interviews with experts in the field of pharmaceutical marketing. Highlights of presentations from industry conferences, contact lists for experts consulted, and links to references help susbcribers keep up to date on best practices and network with their peers.

Blogging My Way Into 2005!

I love blogging! Blogging is less formal than other types of web-based publishing. You can be more opinionated and you can publish your thoughts any time you feel the urge. I like it because I often have opinions on pharma issues as they arise and blogging allows me to publish those opinions immediately and with little hassle.

OpEd: Corporate “Moral Values” Anyone?

A few days after Merck pulled Vioxx from the market it was revealed that the drug manufacturer may have known about Vioxx's cardiovascular side effect problems for years and tried very hard to conceal the evidence and block any action by the FDA. While this was going on an estimated 27,000 people suffered heart attacks and who knows how many strokes possibly due to Vioxx! hard to conceal the evidence and block any action by the FDA. While this was going on an estimated 27,000 people suffered heart attacks and who knows how many strokes possibly due to Vioxx! If this obstructionism by Merck is true, then someone should pay.

Pharma Marketing News Vol. 3, #10 Archive

Dear Reader, Welcome to the November/December 2004 archive of Pharma Marketing News. Vol. 3, No. 10: November/December 2004 - CONTENTS...

The Truth About the Drug Companies: What To Do About It

You can't go to a pharma industry conference these days without hearing at least one expert speaker recommending that pharma executives read the book 'The Truth About the Drug Companies: How They Deceive Us and What to do About It,' written by Marcia Angell, MD, former editor in chief of The New England Journal of Medicine. This review includes several point-counter point views regarding Angell's arguments by pharmaceutical and healthcare experts, including members of the PHARMA-MKTING online discussion group.

Creating a Successful DTC Campaign on the Inside

While most major direct-to-consumer (DTC) advertising campaigns in the medical device and pharmaceutical industries are created and managed by outside agencies, outsourcing a DTC marketing campaign can be expensive. When budgets are lean-as they are in today's marketplace-marketers need to look at how much can be done with in-house resources. But with fewer people being asked to do more than ever, how does a company handle bringing more of the work in-house?

A Novel Approach to Communicating with Physicians

This article describes a patent-pending technology developed by MagicMedia Communications. It offers a novel way for pharmaceutical sales representatives to 'talk' to a doctor…even when face-to-face discussion is not possible!

Is Your Medical Device Ready for Consumers?

It's not always clear whether your marketing dollars should be spent on DTC marketing. Amy Siegel, Vice President, Health Advances, LLC, a healthcare strategy consulting company located in Weston, MA, offered some clear advice on how to determine if DTC is appropriate for a medical device.

Will COX-2 Inhibitors Crash and Burn?

This article documents the effect of the withdrawal of Vioxx and other COX-2 revelations on physicians' prescribing behavior using data from ImpactRx. Also included are results from a recent survey we conducted of Pharma Marketing News susbcribers regarding the wisdom of Pfizer's decision to test Celebrex to see if it is able to prevent heart attacks and strokes in patients with serious cardiovascular disease.

Will COX-2 Inhibitors Crash and Burn?

This article documents the effect of the withdrawal of Vioxx and other COX-2 revelations on physicians' prescribing behavior using data from ImpactRx. Also included are results from a recent survey we conducted of Pharma Marketing News susbcribers regarding the wisdom of Pfizer's decision to test Celebrex to see if it is able to prevent heart attacks and strokes in patients with serious cardiovascular disease.

Pharma Marketing News, Blog Posts, Events, Podcasts

- Advertisement -